Key result
Direct oral anticoagulants (DOACs) have become the first-line treatment for stroke prevention in patients with nonvalvular atrial fibrillation due to a reduced risk of major bleeding compared to warfarin.
No takes yet. Share an insight, caveat, or question.
According to the World Health Organization, during the next few decades, the burden of cardiovascular and cerebrovascular diseases, the 2 leading causes of death globally, will increase further as the world population ages. Approximately one-fourth to one-third of people will die of acute vascular diseases.1 Thus, primary and secondary antithrombotic prevention plays a key role in reducing this burden. Prescription of oral anticoagulants has increased in recent years,2 with at least 4 new direct oral anticoagulants (DOACs) emerging as alternatives to warfarin in different clinical scenarios. Compared to warfarin, DOACs have reduced risk of major bleeding, especially intracranial hemorrhages. Therefore, DOACs have become the first-line treatment for stroke prevention in patients with nonvalvular atrial fibrillation.
Dias et al. (2020) conducted a review in Stroke in patients on dabigatran. Idarucizumab before reperfusion therapy was evaluated. Direct oral anticoagulants (DOACs) have become the first-line treatment for stroke prevention in patients with nonvalvular atrial fibrillation due to a reduced risk of major bleeding compared to warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: